MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcin.2021.08.058

Медицинская библиотека · JACC. Cardiovascular interventions · 2021

Vascular Quality Initiative Surveillance of Femoropopliteal Artery Paclitaxel Devices.

Bertges Daniel J, Eldrup-Jorgensen Jens, Robbins Susan, Ssemaganda Henry, Malone Misti, Marinac-Dabic Danica, Smale Joshua, Lottes Aaron E, Majithia Arjun, Resnic Frederic S, Society for Vascular Surgery Vascular Quality Initiative

СтатьяМетаанализПоддержка службы здравоохранения СШАПеревод пока не подготовлен

Аннотация

OBJECTIVES

This study sought to determine the safety and efficacy of paclitaxel (PTX) devices in the treatment of peripheral artery disease involving the femoropopliteal artery.

BACKGROUND

A meta-analysis of PTX devices for the treatment of femoropopliteal artery disease reported a mortality signal.

METHODS

This was a multicenter cohort study using an integrated clinical data surveillance system to conduct a prospective, propensity score-matched survival analysis of 2,456 patients in the Society for Vascular Surgery Vascular Quality Initiative from January 2017 to May 2020. The study compared PTX drug-coated balloon angioplasty versus percutaneous transluminal balloon angioplasty, PTX drug-eluting stents versus bare-metal stents, and any PTX device versus any non-PTX device. The primary outcome was 2-year survival. Secondary endpoints were successful ambulation and interventional success.

RESULTS

Treatment with any PTX device versus any non-PTX device was associated with increased 2-year survival (89.5% vs 86.7%; HR: 0.79; 95% CI: 0.72-0.87; P = 0.004), improved interventional success (81.6% vs 77.6%; HR: 0.82; 95% CI: 0.74-0.91; P < 0.001), and higher rates of independent ambulation at 1 year (86.0% vs 83.4%; HR: 0.85; 95% CI: 0.79-0.91; P = 0.008). Treatment with PTX drug-coated balloon angioplasty was associated with improved survival at 2 years (88.9% vs 85.7%; HR: 0.77; 95% CI: 0.70-0.86; P = 0.005), while PTX drug-eluting stent therapy was associated with similar survival compared with bare-metal stent therapy (91.3% vs 89.6%; HR: 0.84; 95% CI: 0.70-1.01; P = 0.36).

CONCLUSIONS

In this prospective, active surveillance of a national clinical registry, PTX-containing devices were associated with increased survival at 2 years and improved clinical outcomes at 1 year. (VQI DELTA Paclitaxel Device Safety Analysis [VQI-PTX]; NCT04110288).

Для цитирования: Bertges Daniel J, Eldrup-Jorgensen Jens, Robbins Susan, Ssemaganda Henry, Malone Misti, Marinac-Dabic Danica, Smale Joshua, Lottes Aaron E, Majithia Arjun, Resnic Frederic S, Society for Vascular Surgery Vascular Quality Initiative. Vascular Quality Initiative Surveillance of Femoropopliteal Artery Paclitaxel Devices.. JACC. Cardiovascular interventions. 2021. DOI: 10.1016/j.jcin.2021.08.058.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.